Linked Data API

Show Search Form

Search Results

1132403
unstar this property registered interest false more like this
unstar this property date less than 2019-06-17more like thismore than 2019-06-17
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
unstar this property hansard heading Orkambi more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
unstar this property question text To ask the Secretary of State for Health and Social Care, what contingency plans his Department has put in place in the event that Vertex declines NHS England’s latest offer for the supply of Orkambi. more like this
star this property tabling member constituency Birmingham, Selly Oak more like this
star this property tabling member printed
Steve McCabe more like this
star this property uin 265417 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer remove filter
star this property answer text <p>NHS England is leading the negotiations with Vertex and has made a revised and improved offer to Vertex that would provide immediate funding for Orkambi, and Symkevi in advance of assessment by the National Institute for Health and Care Excellence (NICE), and expanded access to Kalydeco which is already funded on the National Health Service for certain patients.</p><p>The Government fully supports NICE and NHS England in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department’s approach remains to urge Vertex to accept NHS England’s generous offer, but we will explore other options to ensure patients can access treatments as soon as possible.</p> more like this
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy remove filter
star this property grouped question UIN 265418 more like this
star this property question first answered
less than 2019-06-20T09:33:36.433Zmore like thismore than 2019-06-20T09:33:36.433Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
298
unstar this property label Biography information for Steve McCabe more like this
1132404
unstar this property registered interest false more like this
unstar this property date less than 2019-06-17more like thismore than 2019-06-17
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
unstar this property hansard heading Orkambi: Clinical Trials more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
unstar this property question text To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of launching a large scale clinical trial of the generic version of Orkambi. more like this
star this property tabling member constituency Birmingham, Selly Oak more like this
star this property tabling member printed
Steve McCabe more like this
star this property uin 265418 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer remove filter
star this property answer text <p>NHS England is leading the negotiations with Vertex and has made a revised and improved offer to Vertex that would provide immediate funding for Orkambi, and Symkevi in advance of assessment by the National Institute for Health and Care Excellence (NICE), and expanded access to Kalydeco which is already funded on the National Health Service for certain patients.</p><p>The Government fully supports NICE and NHS England in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department’s approach remains to urge Vertex to accept NHS England’s generous offer, but we will explore other options to ensure patients can access treatments as soon as possible.</p> more like this
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy remove filter
star this property grouped question UIN 265417 more like this
star this property question first answered
less than 2019-06-20T09:33:36.47Zmore like thismore than 2019-06-20T09:33:36.47Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
298
unstar this property label Biography information for Steve McCabe more like this
1132424
unstar this property registered interest false more like this
unstar this property date less than 2019-06-17more like thismore than 2019-06-17
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
unstar this property hansard heading Skin Cancer more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
unstar this property question text To ask the Secretary of State for Health and Social Care, what steps he is taking to reduce the number of cases of melanoma. more like this
star this property tabling member constituency East Londonderry more like this
star this property tabling member printed
Mr Gregory Campbell more like this
star this property uin 265456 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer remove filter
star this property answer text <p>On 16 June 2014, a local pilot campaign launched in Devon, Cornwall and Somerset to raise awareness of the signs of skin cancer. It encouraged people to tell their doctor if they noticed any unusual or persistent changes to their skin. It ran until 27 July 2014 and included adverts in the press and on local radio, as well as some direct mail to the target group.</p><p> </p><p>Skin Cancer awareness month is an annual awareness campaign that takes place every May. The campaign aims to raise awareness of the dangers of unprotected sun exposure and educate the public about the ways to help prevent skin cancer.</p><p>The Sunbeds (Regulation) Act 2010 came into force in April 2011 in England and Wales to prohibit under-18s from using sunbeds.</p><p> </p><p>Public Health England (PHE) contributed to the revision of the World Health Organization publication “Artificial tanning devices - Public health interventions to manage sunbeds”, which was published in 2017. PHE advises that sunbeds emit ultraviolet radiation, which can cause tanning and sunburn.</p><p> </p><p><strong> </strong></p><p><strong> </strong></p>
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy remove filter
star this property question first answered
less than 2019-06-20T14:14:40.09Zmore like thismore than 2019-06-20T14:14:40.09Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
1409
unstar this property label Biography information for Mr Gregory Campbell more like this
1132431
unstar this property registered interest false more like this
unstar this property date less than 2019-06-17more like thismore than 2019-06-17
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
unstar this property hansard heading Pharmacy Integration Fund more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
unstar this property question text To ask the Secretary of State for Health and Social Care, what the current balance of the pharmacy integration fund is; and what initiatives have been supported by that fund since its inception. more like this
star this property tabling member constituency Rother Valley more like this
star this property tabling member printed
Sir Kevin Barron more like this
star this property uin 265429 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer remove filter
star this property answer text <p>NHS England and NHS Improvement are awaiting the completion of the annual audit of its accounts, therefore no final figure is currently available for the balance of the Pharmacy Integration Fund (PhIF). The PhIF has supported a range of initiatives, including:</p><p>- Recruitment and training of pharmacists to support integrated urgent care services, offering patients and care staff direct access to clinical advice and care from pharmacists;</p><p>- Putting pharmacists and pharmacy technicians into the multi-disciplinary teams delivering enhanced health in care homes, to support medicines optimisation for people who live in care homes;</p><p>- The development of an urgent medicines supply service. This connects people who contact NHS 111 for urgent access to medicines with local community pharmacies who are able to dispense, and redirects demand out of general practitioner out of hours services, and/or accident and emergency departments;</p><p>- The piloting of a minor illness service, which enables people who contact NHS 111 to get urgent care and advice from a local community pharmacy for a range of common illness complaints; and</p><p>- Providing leadership training for the profession to support them to work effectively with their partners in the emerging integrated care systems, with a focus on delivering the range of benefits of medicines optimisation.</p><p>Further information can be found on NHS England’s website and accessed via the following link:</p><p><a href="https://www.england.nhs.uk/primary-care/pharmacy/pharmacy-integration-fund/" target="_blank">https://www.england.nhs.uk/primary-care/pharmacy/pharmacy-integration-fund/</a></p>
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy remove filter
star this property question first answered
less than 2019-06-20T14:13:14.627Zmore like thismore than 2019-06-20T14:13:14.627Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
392
unstar this property label Biography information for Sir Kevin Barron more like this
1132599
unstar this property registered interest false more like this
unstar this property date less than 2019-06-17more like thismore than 2019-06-17
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
unstar this property hansard heading Out-patients: Attendance more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
unstar this property question text To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the cost to the public purse of missed (a) GP and (b) hospital appointments. more like this
star this property tabling member constituency Tewkesbury more like this
star this property tabling member printed
Mr Laurence Robertson more like this
star this property uin 265416 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer remove filter
star this property answer text <p>Information surrounding the cost of missed general practitioner and hospital appointments is not collected or held centrally.</p> more like this
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy remove filter
star this property question first answered
less than 2019-06-20T09:32:08.917Zmore like thismore than 2019-06-20T09:32:08.917Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
253
unstar this property label Biography information for Mr Laurence Robertson more like this
1132036
unstar this property registered interest false more like this
unstar this property date less than 2019-06-13more like thismore than 2019-06-13
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
unstar this property hansard heading General Practitioners more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
unstar this property question text To ask the Secretary of State for Health and Social Care, what criteria his Department plans to use to assess Primary Care Networks’ engagement with local communities. more like this
star this property tabling member constituency Newton Abbot more like this
star this property tabling member printed
Anne Marie Morris more like this
star this property uin 264407 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer remove filter
star this property answer text <p>For Primary Care Networks (PCNs) to be successful they will need to work in partnership with local people and the communities they serve. NHS England does have a statutory duty to undertake an annual assessment of clinical commissioning groups’ (CCGs) performance, as part of the CCG Improvement and Assessment Framework (IAF). One of the indicators assessed is patient and community engagement. All NHS service providers, including general practitioner practices, have legal duties to engage with local authority health scrutiny about changes which may be considered substantial. These duties which currently apply to NHS service providers and commissioners around engagement and consultation will continue to be valid.</p><p>Further information on the IAF is available on the NHS England website at the following link:</p><p><a href="https://www.england.nhs.uk/commissioning/regulation/ccg-assess/" target="_blank">https://www.england.nhs.uk/commissioning/regulation/ccg-assess/</a></p><p>Results from the assessments are published on ‘MyNHS’ at the following link:</p><p><a href="https://www.nhs.uk/service-search/performance-indicators/organisations/ccg-year-end-2015-assurance-assessment" target="_blank">https://www.nhs.uk/service-search/performance-indicators/organisations/ccg-year-end-2015-assurance-assessment</a></p><p>The assessments made are in line with the document ‘Patient and public participation in commissioning health and care: statutory guidance for CCGs and NHS England’, which is at the following link:</p><p><a href="https://www.england.nhs.uk/publication/patient-and-public-participation-in-commissioning-health-and-care-statutory-guidance-for-ccgs-and-nhs-england/" target="_blank">https://www.england.nhs.uk/publication/patient-and-public-participation-in-commissioning-health-and-care-statutory-guidance-for-ccgs-and-nhs-england/</a></p><p> </p><p> </p>
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy remove filter
star this property question first answered
less than 2019-06-20T15:40:56.963Zmore like thismore than 2019-06-20T15:40:56.963Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4249
unstar this property label Biography information for Anne Marie Morris more like this
1131740
unstar this property registered interest false more like this
unstar this property date less than 2019-06-12more like thismore than 2019-06-12
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
unstar this property hansard heading National Institute for Health and Care Excellence more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
unstar this property question text To ask the Secretary of State for Health and Social Care, which topics have been identified for inclusion in the upcoming review of the appraisal methods used by NICE. more like this
star this property tabling member constituency Cambridge more like this
star this property tabling member printed
Daniel Zeichner more like this
star this property uin 263870 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer remove filter
star this property answer text <p>The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for the methods and processes used in the development of its technology appraisal and highly specialised technologies recommendations. NICE has now initiated the review of its technology appraisal and highly specialised technologies methods in line with the commitment made in the 2019 Voluntary Scheme for Branded Medicines Pricing and Access.</p><p> </p><p>The Voluntary Scheme states that industry and other relevant stakeholders will be active participants in the review, including inputting on scope, participating in working discussions, and providing views on recommendations. NICE’s updated methods guide will also be subject to a public consultation.</p><p> </p><p>NICE has established a working group, consisting of members from NICE, NHS England, the Department, patient organisations and the life sciences industry. The working group reports to a steering group, chaired by NICE and with members from NHS England, the Department, and an independent academic methodologist. The steering group will present its recommendations to NICE’s Senior Management Team, which in turn will report to the NICE Board. NICE approached patient groups with experience of NICE and its processes and methods. There are three patient group representatives on the working group with a wide range of experience, covering a range of topic areas, reflecting the programmes under review. Membership of the working group will be published in due course.</p><p> </p><p>NICE is now in the process of scoping the review of the methods for technology appraisal and highly specialised technologies evaluations with input from the working group and steering group. The scope of the review - a list of the aspects of NICE’s current methods that will be considered in the review - will be presented to the NICE Board in July. Additional detail and more information will be made available on the NICE website in due course. NICE anticipates being in a position to confirm the revised methods guide by the end of 2020, following public consultation.</p><p> </p><p><strong> </strong></p><p><strong> </strong></p>
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy remove filter
star this property grouped question UIN
263871 more like this
263872 more like this
263873 more like this
263874 more like this
star this property question first answered
less than 2019-06-20T13:18:08.087Zmore like thismore than 2019-06-20T13:18:08.087Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4382
unstar this property label Biography information for Daniel Zeichner more like this
1131742
unstar this property registered interest false more like this
unstar this property date less than 2019-06-12more like thismore than 2019-06-12
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
unstar this property hansard heading National Institute for Health and Care Excellence more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
unstar this property question text To ask the Secretary of State for Health and Social Care, what the timescale is for NICE's Methods review. more like this
star this property tabling member constituency Cambridge more like this
star this property tabling member printed
Daniel Zeichner more like this
star this property uin 263871 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer remove filter
star this property answer text <p>The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for the methods and processes used in the development of its technology appraisal and highly specialised technologies recommendations. NICE has now initiated the review of its technology appraisal and highly specialised technologies methods in line with the commitment made in the 2019 Voluntary Scheme for Branded Medicines Pricing and Access.</p><p> </p><p>The Voluntary Scheme states that industry and other relevant stakeholders will be active participants in the review, including inputting on scope, participating in working discussions, and providing views on recommendations. NICE’s updated methods guide will also be subject to a public consultation.</p><p> </p><p>NICE has established a working group, consisting of members from NICE, NHS England, the Department, patient organisations and the life sciences industry. The working group reports to a steering group, chaired by NICE and with members from NHS England, the Department, and an independent academic methodologist. The steering group will present its recommendations to NICE’s Senior Management Team, which in turn will report to the NICE Board. NICE approached patient groups with experience of NICE and its processes and methods. There are three patient group representatives on the working group with a wide range of experience, covering a range of topic areas, reflecting the programmes under review. Membership of the working group will be published in due course.</p><p> </p><p>NICE is now in the process of scoping the review of the methods for technology appraisal and highly specialised technologies evaluations with input from the working group and steering group. The scope of the review - a list of the aspects of NICE’s current methods that will be considered in the review - will be presented to the NICE Board in July. Additional detail and more information will be made available on the NICE website in due course. NICE anticipates being in a position to confirm the revised methods guide by the end of 2020, following public consultation.</p><p> </p><p><strong> </strong></p><p><strong> </strong></p>
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy remove filter
star this property grouped question UIN
263870 more like this
263872 more like this
263873 more like this
263874 more like this
star this property question first answered
less than 2019-06-20T13:18:08.15Zmore like thismore than 2019-06-20T13:18:08.15Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4382
unstar this property label Biography information for Daniel Zeichner more like this
1131743
unstar this property registered interest false more like this
unstar this property date less than 2019-06-12more like thismore than 2019-06-12
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
unstar this property hansard heading National Institute for Health and Care Excellence more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
unstar this property question text To ask the Secretary of State for Health and Social Care, whether changes to NICE’s appraisal methods identified during the NICE Methods review will be cost-neutral. more like this
star this property tabling member constituency Cambridge more like this
star this property tabling member printed
Daniel Zeichner more like this
star this property uin 263872 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer remove filter
star this property answer text <p>The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for the methods and processes used in the development of its technology appraisal and highly specialised technologies recommendations. NICE has now initiated the review of its technology appraisal and highly specialised technologies methods in line with the commitment made in the 2019 Voluntary Scheme for Branded Medicines Pricing and Access.</p><p> </p><p>The Voluntary Scheme states that industry and other relevant stakeholders will be active participants in the review, including inputting on scope, participating in working discussions, and providing views on recommendations. NICE’s updated methods guide will also be subject to a public consultation.</p><p> </p><p>NICE has established a working group, consisting of members from NICE, NHS England, the Department, patient organisations and the life sciences industry. The working group reports to a steering group, chaired by NICE and with members from NHS England, the Department, and an independent academic methodologist. The steering group will present its recommendations to NICE’s Senior Management Team, which in turn will report to the NICE Board. NICE approached patient groups with experience of NICE and its processes and methods. There are three patient group representatives on the working group with a wide range of experience, covering a range of topic areas, reflecting the programmes under review. Membership of the working group will be published in due course.</p><p> </p><p>NICE is now in the process of scoping the review of the methods for technology appraisal and highly specialised technologies evaluations with input from the working group and steering group. The scope of the review - a list of the aspects of NICE’s current methods that will be considered in the review - will be presented to the NICE Board in July. Additional detail and more information will be made available on the NICE website in due course. NICE anticipates being in a position to confirm the revised methods guide by the end of 2020, following public consultation.</p><p> </p><p><strong> </strong></p><p><strong> </strong></p>
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy remove filter
star this property grouped question UIN
263870 more like this
263871 more like this
263873 more like this
263874 more like this
star this property question first answered
less than 2019-06-20T13:18:08.213Zmore like thismore than 2019-06-20T13:18:08.213Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4382
unstar this property label Biography information for Daniel Zeichner more like this
1131744
unstar this property registered interest false more like this
unstar this property date less than 2019-06-12more like thismore than 2019-06-12
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
unstar this property hansard heading National Institute for Health and Care Excellence more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
unstar this property question text To ask the Secretary of State for Health and Social Care, what criteria was used by NICE to determine which patient organisations were offered membership of the NICE Methods Working Group. more like this
star this property tabling member constituency Cambridge more like this
star this property tabling member printed
Daniel Zeichner more like this
star this property uin 263873 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer remove filter
star this property answer text <p>The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for the methods and processes used in the development of its technology appraisal and highly specialised technologies recommendations. NICE has now initiated the review of its technology appraisal and highly specialised technologies methods in line with the commitment made in the 2019 Voluntary Scheme for Branded Medicines Pricing and Access.</p><p> </p><p>The Voluntary Scheme states that industry and other relevant stakeholders will be active participants in the review, including inputting on scope, participating in working discussions, and providing views on recommendations. NICE’s updated methods guide will also be subject to a public consultation.</p><p> </p><p>NICE has established a working group, consisting of members from NICE, NHS England, the Department, patient organisations and the life sciences industry. The working group reports to a steering group, chaired by NICE and with members from NHS England, the Department, and an independent academic methodologist. The steering group will present its recommendations to NICE’s Senior Management Team, which in turn will report to the NICE Board. NICE approached patient groups with experience of NICE and its processes and methods. There are three patient group representatives on the working group with a wide range of experience, covering a range of topic areas, reflecting the programmes under review. Membership of the working group will be published in due course.</p><p> </p><p>NICE is now in the process of scoping the review of the methods for technology appraisal and highly specialised technologies evaluations with input from the working group and steering group. The scope of the review - a list of the aspects of NICE’s current methods that will be considered in the review - will be presented to the NICE Board in July. Additional detail and more information will be made available on the NICE website in due course. NICE anticipates being in a position to confirm the revised methods guide by the end of 2020, following public consultation.</p><p> </p><p><strong> </strong></p><p><strong> </strong></p>
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy remove filter
star this property grouped question UIN
263870 more like this
263871 more like this
263872 more like this
263874 more like this
star this property question first answered
less than 2019-06-20T13:18:08.26Zmore like thismore than 2019-06-20T13:18:08.26Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4382
unstar this property label Biography information for Daniel Zeichner more like this